Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Iain Dukes
AddedMar 31, 2024
UpdatedMay 31, 2026
Iain Dukes

Iain Dukes

Board Member, ImageneBio

CrunchbaseLinkedIn

Iain Dukes's Career

ImageneBio
ImageneBio

Boston, MA, US

Board Member· Board
Iovance Biotherapeutics
Iovance Biotherapeutics

San Carlos, CA, US

Board Member· Board
Viriom
Viriom

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Iain Dukes's Career

ImageneBio
ImageneBio
Public$209M682016Boston, MA, US
Board Member· Board

Leadership at ImageneBio

Karen McGovernKaren McGovernCo-Founder
David BonitaDavid BonitaBoard Member
Michelle ZhangMichelle ZhangCo-Founder
Mark ManfrediMark ManfrediCo-Founder
Richard WoosterRichard WoosterBoard Member
Dr. Mark Manfredi Ph.D.Dr. Mark Manfredi Ph.D.CEO

Similar to ImageneBio

Revolution MedicinesRevolution MedicinesRedwood City, CA, USOncology Therapiesest. 2014Revolution MedicinesRedwood City, CA, US · est. 2014

US-based Revolution Medicines, Inc. discovers novel oncology therapies targeting elusive growth pathways globally.

Public · $1.1B246
Traws PharmaTraws PharmaNewtown, PA, USCancer Treatmentsest. 1998Traws PharmaNewtown, PA, US · est. 1998

US-based Onconova Therapeutics, Inc. pioneers novel cancer treatments through small molecule drug discovery.

Public · $177.9M17
Clovis OncologyClovis OncologyBoulder, CO, USCancer Treatmentsest. 2009Clovis OncologyBoulder, CO, US · est. 2009

Clovis Oncology, a global biotech firm, specializes in developing and commercializing cancer treatments.

Public · $145M413
Kronos BioKronos BioSan Mateo, CA, USCancer Therapiesest. 2017Kronos BioSan Mateo, CA, US · est. 2017

UK-based Kronos Bio, Inc. pioneers in discovering and developing therapies for complex cancer targets globally.

Public · $278M105
Iovance Biotherapeutics
Iovance Biotherapeutics
Public5032007San Carlos, CA, US
Board Member· Board

Leadership at Iovance Biotherapeutics

Fred VogtFred VogtCEO
Merrill A. McPeakMerrill A. McPeakBoard Member
Michael WeiserMichael WeiserBoard Member
Maria FardisMaria FardisBoard Member
Wendy DixonWendy DixonBoard Member

Similar to Iovance Biotherapeutics

ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
CancervaxCancervaxSanta Barbara, CA, USCancer Treatmentest. 2021CancervaxSanta Barbara, CA, US · est. 2021

CancerVAX Biotech: Santa Barbara-based medical firm innovating universal cancer treatments.

Seed · $500k13
ImmuCision BiotherapeuticsImmuCision BiotherapeuticsBaltimore, MD, USCancer Therapiesest. 2017ImmuCision BiotherapeuticsBaltimore, MD, US · est. 2017

ImmuCision Biotherapeutics, a Maryland-based software company, innovates in immune cell-based cancer therapies.

Public · $2M5
Viriom
Viriom
Series B$35.4M2002009San Diego, CA, US
CEO· C-Suite · Management

Leadership at Viriom

Gerald YakatanGerald YakatanBoard Member
Janet HammondJanet HammondBoard Member

Similar to Viriom

Virion TherapeuticsVirion TherapeuticsNewark, DE, USImmunotherapy, Vaccinesest. 2018Virion TherapeuticsNewark, DE, US · est. 2018

Virion Therapeutics: A global biotech firm innovating vaccines for cancers and chronic viral infections.

Series B · $14.1M8
Vir BiotechnologyVir BiotechnologySan Francisco, CA, USMedicines, Therapeuticsest. 2016Vir BiotechnologySan Francisco, CA, US · est. 2016

Vir Biotechnology, a clinical-stage firm, develops and commercializes treatments for viral and bacterial diseases in California.

Public · $908.6M576
Globavir BiosciencesGlobavir BiosciencesLos Altos, CA, USTherapeuticsest. 2013Globavir BiosciencesLos Altos, CA, US · est. 2013

Globavir Biosciences: A global biotech firm specializing in therapeutics for infectious diseases.

Public · $11.5M30
VirxsysVirxsysGaithersburg, MD, USTherapiesest. 1998VirxsysGaithersburg, MD, US · est. 1998

VIRxSYS Corp, a private biotech firm, innovates therapies for serious human diseases.

Pre-Seed · $102.9M30

Iain Dukes's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Iain Dukes

Jeff KingJeff KingCo-Founder & CEO · VirogenomicsRon DemuthRon DemuthCo-Founder · Teal VenturesEd BrinskeleEd BrinskeleFounder · Vir2usMarianne De BackerMarianne De BackerBoard Member · Arrowhead PharmaceuticalsDave FurneauxDave FurneauxFounder · Furneaux Capital